NASDAQ:BNGO Bionano Genomics (BNGO) Stock Price, News & Analysis $1.38 +0.02 (+1.10%) As of 03:28 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Bionano Genomics Stock (NASDAQ:BNGO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Bionano Genomics alerts:Sign Up Key Stats Today's Range$1.36▼$1.4250-Day Range$1.08▼$1.8352-Week Range$1.00▼$2.23Volume129,533 shsAverage Volume466,080 shsMarket Capitalization$16.20 millionP/E RatioN/ADividend YieldN/APrice Target$6.00Consensus RatingHold Company Overview Bionano Genomics, Inc. is a life sciences company that develops genomic analysis solutions based on optical genome mapping (OGM). Its technology is designed to identify structural variations and other genomic abnormalities that may be difficult to detect with traditional sequencing and cytogenetic methods. The company’s principal platform is the Saphyr system, which includes instrumentation, consumables and software for analyzing ultra-long DNA molecules. Bionano also provides data-analysis tools and informatics solutions intended to support research and clinical workflows in areas such as constitutional genetics, oncology and hematologic malignancies. Bionano Genomics serves academic, government, pharmaceutical and biotechnology researchers, as well as clinical laboratories in the United States and international markets. The company was founded in 2003 and is headquartered in San Diego, California. Its leadership has included Erik Holmlin, who has served as president and chief executive officer.AI Generated. May Contain Errors. Read More Bionano Genomics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreBNGO MarketRank™: 2.62452359048 of 5 starsBionano Genomics scored higher than 52% of companies evaluated by MarketBeat, and ranked 512th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingBionano Genomics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialBionano Genomics has a consensus price target of $6.00, representing about 327.0% upside from its current price of $1.41.Amount of Analyst CoverageBionano Genomics has only been the subject of 1 research reports in the past 90 days.Read more about Bionano Genomics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Bionano Genomics is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bionano Genomics is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBionano Genomics has a P/B Ratio of 0.32. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Bionano Genomics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.39% of the float of Bionano Genomics has been sold short.Short Interest Ratio / Days to CoverBionano Genomics has a short interest ratio ("days to cover") of 2.08, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bionano Genomics has recently increased by 77.86%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBionano Genomics does not currently pay a dividend.Dividend GrowthBionano Genomics does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.41 News SentimentBionano Genomics has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Bionano Genomics this week, compared to 3 articles on an average week.Search Interest3 people have searched for BNGO on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Bionano Genomics to their MarketBeat watchlist in the last 30 days. Company Ownership3.0 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $9,720.00 in company stock, which represents 0.0587% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Bionano Genomics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $9,720.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders0.65% of the stock of Bionano Genomics is held by insiders.Percentage Held by Institutions11.35% of the stock of Bionano Genomics is held by institutions.Read more about Bionano Genomics' insider trading history. Receive BNGO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bionano Genomics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BNGO Stock News HeadlinesBionano Genomics consensus price target increased by 21.14% to MX$100.98October 4, 2026 | msn.comBionano Laboratories Announces Expansion of Diagnostic Testing Based on Optical Genome Mapping for Hematologic MalignanciesSeptember 23, 2026 | globenewswire.comElon will prove them wrong againElon Musk's critics said self-driving cars were a pipe dream. Today, Tesla robotaxis carry passengers with no driver in major U.S. cities. Veteran tech investor James Altucher says Musk is applying the same playbook to a new project he calls his infinite money glitch, expected to launch October 21. Altucher, who has tracked tech breakthroughs for nearly four decades, calls this the biggest one he has ever covered.October 14 at 1:00 AM | Paradigm Press (Ad)Bionano: OGM Studies Reveal High-Risk Genomic Alterations Missed By Standard CytogeneticsSeptember 14, 2026 | rttnews.comBionano Announces Three New Peer-Reviewed Studies Demonstrate Clinical Value of Bionano's Optical Genome Mapping Across Myelodysplastic Syndromes and Acute Myeloid LeukemiaSeptember 14, 2026 | globenewswire.comBionano Announces Proposed Medicare Coverage For Genome-Wide Hematologic Cancer TestingSeptember 10, 2026 | rttnews.comBionano Laboratories Announces Proposed Local Coverage Determination (LCD) from MolDX for Genome-Wide Detection of Structural Variants in Hematologic NeoplasmsSeptember 10, 2026 | globenewswire.comBionano Laboratories Announces New York State Department of Health Approval of Lab Developed Tests Based on Optical Genome MappingSeptember 8, 2026 | globenewswire.comSee More Headlines BNGO Stock Analysis - Frequently Asked Questions How have BNGO shares performed this year? Bionano Genomics' stock was trading at $1.53 at the beginning of the year. Since then, BNGO shares have decreased by 8.2% and is now trading at $1.4050. How were Bionano Genomics' earnings last quarter? Bionano Genomics, Inc. (NASDAQ:BNGO) announced its earnings results on Monday, August, 10th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.67) by $0.03. The firm had revenue of ($6.67) million for the quarter, compared to analyst estimates of $7.55 million. Bionano Genomics had a negative net margin of 106.58% and a negative trailing twelve-month return on equity of 78.78%. Read the conference call transcript. When did Bionano Genomics' stock split? Bionano Genomics's stock reverse split on Monday, January 27th 2025.The 1-60 reverse split was announced on Wednesday, January 22nd 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 24th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. When did Bionano Genomics IPO? Bionano Genomics (BNGO) raised $30 million in an initial public offering on Friday, September 21st 2018. The company issued 5,500,000 shares at $5.00-$6.00 per share. How do I buy shares of Bionano Genomics? Shares of BNGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bionano Genomics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bionano Genomics investors own include NIO (NIO), Tesla (TSLA), Palantir Technologies (PLTR), Nano Dimension (NNDM), Plug Power (PLUG), FuelCell Energy (FCEL) and Ocugen (OCGN). Company Calendar Last Earnings8/10/2026Today10/14/2026Next Earnings (Estimated)10/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 3 weeks, BNGO's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:BNGO CIK1411690 Webwww.bionano.com Phone(858) 888-7600FaxN/AEmployees97Year Founded2002Price Target and Rating Average Price Target for Bionano Genomics$6.00 High Price Target$6.00 Low Price Target$6.00 Potential Upside/Downside+336.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($3.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.40 million Net Margins-106.58% Pretax Margin-106.36% Return on Equity-78.78% Return on Assets-48.54% Debt Debt-to-Equity Ratio0.11 Current Ratio2.48 Quick Ratio1.96 Sales & Book Value Annual Sales$28.51 million Price / Sales0.57 Cash FlowN/A Price / Cash FlowN/A Book Value$4.37 per share Price / Book0.31Miscellaneous Outstanding Shares11,780,000Free Float11,700,000Market Cap$16.20 million OptionableNo Data Beta1.66 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:BNGO) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersMicroscopic footage reveals immune cells destroying cancer cellsTime-lapse footage from a recent clinical study shows Natural Killer cells attacking and eliminating cancer ce...Market Tactic | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredElon pays this company. Every time.Every Tesla built since 2012 pays this small, overlooked supplier a fee for its technology. So does every Star...Behind the Markets | SponsoredElon will prove them wrong againElon Musk's critics said self-driving cars were a pipe dream. Today, Tesla robotaxis carry passengers with no ...Paradigm Press | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredDid you grab your copy yet?Bill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarte...Profits Run | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bionano Genomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bionano Genomics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
